Mark X. Sliwkowski
Impact in
- Oncology top 0.05%
- HER2/EGFR in Cancer Research
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- Radiology, Nuclear Medicine and Imaging top 0.02%
- Monoclonal and Polyclonal Antibodies Research
Papers in
- Oncology 86
- HER2/EGFR in Cancer Research 82
- Peptidase Inhibition and Analysis 10
-
- Monoclonal and Polyclonal Antibodies Research 71
- Radiopharmaceutical Chemistry and Applications 8
- Co-authors
- Yosef Yarden (1 shared paper)Charles Eigenbrot (3 shared papers)Robert W. Akita (19 shared papers)Gail D. Lewis Phillips (18 shared papers)Jennifer L. Stamos (1 shared paper)Kathryn L. Parsons (6 shared papers)Ira Mellman (3 shared papers)Daniel J. Leahy (2 shared papers)
- Journals
- Cancer Research (14 papers)Journal of Biological Chemistry (12 papers)Journal of Clinical Oncology (7 papers)Clinical Cancer Research (5 papers)Oncogene (4 papers)
- Partner nations
- United StatesUnited KingdomIsrael
In The Last Decade
Mark X. Sliwkowski
111 papers receiving 21.3k citations
Mark X. Sliwkowski's Hit Papers
Peers
Comparison fields: 5 of 143
- Oncology 14.5k
- Radiology, Nuclear Medicine and Imaging 9.8k
- Immunology and Allergy 1.2k
- Molecular Biology 9.9k
- Pulmonary and Respiratory Medicine 3.4k
Countries citing papers authored by Mark X. Sliwkowski
This map shows the geographic impact of Mark X. Sliwkowski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark X. Sliwkowski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark X. Sliwkowski more than expected).
Fields of papers citing papers by Mark X. Sliwkowski
This network shows the impact of papers produced by Mark X. Sliwkowski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark X. Sliwkowski. The network helps show where Mark X. Sliwkowski may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark X. Sliwkowski, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 111 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Untangling the ErbB signalling network Hit paper breakdown → | 2001 | 5466 |
| 2 | Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate Hit paper breakdown → | 2008 | 1259 |
| 3 | Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor Hit paper breakdown → | 2002 | 1202 |
| 4 | Identification of Heregulin, a Specific Activator of p185 erbB2 Hit paper breakdown → | 1992 | 845 |
| 5 | Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex Hit paper breakdown → | 2004 | 828 |
| 6 | Treatment of HER2-positive breast cancer: current status and future perspectives Hit paper breakdown → | 2011 | 696 |
| 7 | An Open-and-Shut Case? Recent Insights into the Activation of EGF/ErbB Receptors Hit paper breakdown → | 2003 | 669 |
| 8 | Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941 Hit paper breakdown → | 2009 | 651 |
| 9 | Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. Hit paper breakdown → | 1994 | 560 |
| 10 | Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers Hit paper breakdown → | 1999 | 540 |
| 11 | A Central Role for HER3 in HER2 -Amplified Breast Cancer: Implications for Targeted Therapy Hit paper breakdown → | 2008 | 501 |
| 12 | Antibody Therapeutics in Cancer Hit paper breakdown → | 2013 | 446 |
| 13 | 2010 | 437 | |
| 14 | 2010 | 411 | |
| 15 | 2004 | 397 | |
| 16 | Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. | 1993 | 351 |
| 17 | 2011 | 344 | |
| 18 | 2006 | 334 | |
| 19 | 1994 | 312 | |
| 20 | Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. | 2000 | 310 |
About Mark X. Sliwkowski
Mark X. Sliwkowski is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging, Molecular Biology, Pulmonary and Respiratory Medicine and Immunology, having authored 111 papers that have together received 21.9k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (82 papers), Monoclonal and Polyclonal Antibodies Research (71 papers), Glycosylation and Glycoproteins Research (16 papers), Lung Cancer Treatments and Mutations (11 papers), Peptidase Inhibition and Analysis (10 papers), Radiopharmaceutical Chemistry and Applications (8 papers), Cell Adhesion Molecules Research (7 papers) and Selenium in Biological Systems (6 papers). The work is most often cited by research in Oncology (14.5k citations), Radiology, Nuclear Medicine and Imaging (9.8k citations), Immunology and Allergy (1.2k citations), Molecular Biology (9.9k citations) and Pulmonary and Respiratory Medicine (3.4k citations). Mark X. Sliwkowski has collaborated with scholars based in United States, United Kingdom and Israel. Frequent co-authors include Yosef Yarden, Charles Eigenbrot, Robert W. Akita, Gail D. Lewis Phillips, Jennifer L. Stamos, Kathryn L. Parsons, Ira Mellman, Daniel J. Leahy, Lisa Crocker and Guangmin Li. Their work appears in journals such as Cancer Research, Journal of Biological Chemistry, Journal of Clinical Oncology, Clinical Cancer Research and Oncogene.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.